Hims & Hers Expands Access to Affordable Generic Semaglutide in Canada
Hims & Hers Health, Inc. has announced the launch of generic semaglutide for eligible customers in Canada, marking a major milestone in the country’s evolving healthcare and weight management landscape. The move is expected to significantly improve access to GLP-1 therapies for Canadians who have historically struggled with the high costs associated with obesity and metabolic health treatments.
The introduction of generic semaglutide through the Hims & Hers platform comes at a time when demand for effective weight management solutions continues to surge globally. With nearly two-thirds of Canadian adults classified as overweight or obese, healthcare providers and policymakers have increasingly emphasized the need for more accessible and affordable treatment options. By offering personalized treatment plans starting at CAD 149 per month, Hims & Hers aims to remove financial barriers that have prevented many Canadians from accessing modern obesity care.
Semaglutide, a GLP-1 receptor agonist, has become one of the most recognized and clinically effective medications for weight management and metabolic health improvement. Originally developed for diabetes management, GLP-1 therapies have demonstrated substantial benefits in helping patients achieve sustainable weight loss while also supporting broader health outcomes such as improved cardiovascular health, blood sugar regulation, and reduced obesity-related complications.
The approval of generic semaglutide by Health Canada is widely viewed as a transformative moment for the Canadian healthcare market. Until now, many patients faced limited access to GLP-1 medications because of high pricing and inconsistent insurance coverage. The availability of generic alternatives is expected to encourage broader competition in the market, ultimately driving down prices and increasing treatment accessibility across the country.
Hims & Hers stated that its Canadian platform will offer eligible clients comprehensive, personalized care plans that extend beyond medication alone. In addition to GLP-1 therapy options, customers will receive ongoing support from licensed healthcare providers and access to evidence-based resources focused on nutrition, exercise, sleep, and long-term lifestyle improvement. The company emphasized that sustainable health outcomes require more than prescriptions and that individualized care remains central to its approach.
A key component of the company’s Canadian expansion strategy is its focus on localized healthcare expertise. All patients in Canada using the platform will be connected with Canadian healthcare providers who understand the country’s regulatory framework, healthcare system, and patient needs. Hims & Hers says this localized model ensures clinical quality while also creating a more seamless experience for patients seeking obesity and metabolic health treatment.
Dr. Sandy Van, obesity medicine specialist and Medical Director for Hims & Hers Canada, described the launch as a significant advancement in patient care and affordability. According to Dr. Van, generic medications have historically played a crucial role in expanding access to life-changing treatments, and the arrival of generic semaglutide represents a new era of patient choice and affordability.
She emphasized that obesity care should be centered around the whole patient rather than simply focusing on weight loss alone. By integrating medical treatment with behavioral health support, nutrition guidance, and ongoing clinical oversight, Hims & Hers hopes to create a more comprehensive care ecosystem for Canadians struggling with obesity and related health conditions.
Austin Kouri, Managing Director of Hims & Hers Canada, also highlighted the broader implications of introducing affordable GLP-1 therapies into the Canadian market. He noted that increasing patient choice and lowering costs can strengthen the healthcare system overall by making clinically proven treatments more widely available.
Kouri explained that the company’s goal is not only to provide medication access but also to help modernize healthcare delivery in Canada through digital-first care solutions. Telehealth platforms such as Hims & Hers have gained significant traction in recent years, particularly among patients seeking more convenient and discreet access to healthcare services. By combining virtual consultations, ongoing provider communication, and home delivery services, digital healthcare platforms are increasingly reshaping how Canadians manage chronic health conditions.
The launch of generic semaglutide may also intensify competition within the broader GLP-1 market. As more providers begin offering affordable alternatives, industry analysts expect continued downward pressure on pricing, which could further expand treatment adoption nationwide. Increased competition may also encourage innovation in patient support services, digital healthcare integration, and personalized treatment models.
The rising popularity of GLP-1 medications has sparked global conversations about obesity treatment and preventative healthcare. Medical experts increasingly recognize obesity as a chronic disease requiring long-term management rather than short-term interventions. As awareness grows, demand for accessible and evidence-based obesity care solutions continues to rise among patients and healthcare systems alike.
For many Canadians, cost has remained one of the largest obstacles to treatment. Brand-name GLP-1 medications often carry monthly costs that are unaffordable for uninsured or underinsured patients. The introduction of lower-cost generic alternatives through platforms like Hims & Hers could dramatically shift the accessibility landscape by enabling more individuals to begin medically supervised treatment programs.
Hims & Hers also stressed that its care model is designed to support long-term health behavior changes rather than quick fixes. Clients using the platform will have ongoing access to care teams who can monitor progress, adjust treatment plans when necessary, and provide support tailored to each patient’s individual goals and medical history.
The company believes this integrated approach can improve both adherence and long-term outcomes. Research has shown that combining medication with behavioral support, nutrition counseling, and physical activity guidance often produces more sustainable health improvements than medication alone.
As digital healthcare adoption continues to grow across Canada, the expansion of virtual obesity care services may play an increasingly important role in addressing public health challenges. Telehealth platforms can help reduce geographic barriers, shorten wait times, and provide patients with faster access to specialized care providers, particularly in underserved regions.
The launch also reflects a broader trend toward consumer-focused healthcare models that prioritize accessibility, personalization, and convenience. Patients are increasingly seeking healthcare experiences that fit into their daily lives, and digital health companies are responding by creating more streamlined and patient-centric services.
With the addition of generic semaglutide to its Canadian platform, Hims & Hers is positioning itself at the forefront of this transformation. The company says its mission remains focused on empowering Canadians with the tools, support, and medical expertise needed to take greater control of their long-term health and wellness.
As the Canadian healthcare market continues to evolve, the availability of affordable GLP-1 therapies could represent a major turning point for obesity treatment nationwide. By lowering costs and expanding access through digital care platforms, companies like Hims & Hers may help reshape how chronic health conditions are treated in the years ahead.
About Hims & Hers Health, Inc.
Hims & Hers is the leading health and wellness platform with a mission to help the world feel good through the power of better health. We believe that how you feel in your body and mind transforms how you experience life. That’s why we’re building a future where nothing stands in the way of that power. Hims & Hers normalizes health and wellness challenges and finds innovative solutions to make feeling happy and healthy easy to achieve. Every person is unique, which is why the company provides access to personalized care designed to deliver results.
